DrugPatentWatch Database Preview
Drugs in Development Information for Dalcetrapib
Drug Development Status for Dalcetrapib: Sponsors, patents, clinical trial progress
Dalcetrapib is an investigational drug.
There have been 13 clinical trials for Dalcetrapib.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2015.
The most common disease conditions in clinical trials are Myocardial Ischemia, Heart Diseases, and Coronary Disease. The leading clinical trial sponsors are Hoffmann-La Roche, Medpace, Inc., and Dr. Reddy's Laboratories Limited.
There are one hundred and fifty-six US patents protecting this investigational drug and two international patents.
Summary for Dalcetrapib
| US Patents | 156 |
| International Patents | 2,396 |
| US Patent Applications | 289 |
| WIPO Patent Applications | 167 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 3 (2015-11-01) |
| Vendors | 67 |
Recent Clinical Trials for Dalcetrapib
| Title | Sponsor | Phase |
|---|---|---|
| Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS | Medpace, Inc. | Phase 3 |
| Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS | Roche Molecular Systems, Inc | Phase 3 |
| Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS | The Montreal Health Innovations Coordinating Center (MHICC) | Phase 3 |
Clinical Trial Summary for Dalcetrapib
Top disease conditions for Dalcetrapib
Top clinical trial sponsors for Dalcetrapib
US Patents for Dalcetrapib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Dalcetrapib | See Pricing | Pharmaceutical compositions with enhanced performance and improved processability | HERCULES LLC (Wilmington, DE) | See Pricing |
| Dalcetrapib | See Pricing | CETP activity inhibitors | Japan Tobacco Inc. (Tokyo, JP) | See Pricing |
| Dalcetrapib | See Pricing | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE) | See Pricing |
| Dalcetrapib | See Pricing | CETP activity inhibitor | Japan Tobacco Inc. (Tokyo, JP) | See Pricing |
| Dalcetrapib | See Pricing | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (Frankfurt Am Main, DE) | See Pricing |
| Dalcetrapib | See Pricing | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | Pfizer Inc. (New York, NY) | See Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Dalcetrapib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Dalcetrapib | Brazil | 112015021179 | 2033-03-01 | See Pricing |
| Dalcetrapib | Canada | 2899546 | 2033-03-01 | See Pricing |
| Dalcetrapib | China | 105073783 | 2033-03-01 | See Pricing |
| Dalcetrapib | European Patent Office | 2961775 | 2033-03-01 | See Pricing |
| Dalcetrapib | Japan | 2016510080 | 2033-03-01 | See Pricing |
| Dalcetrapib | Japan | 6456849 | 2033-03-01 | See Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
